A phase II trial of perioperative CapeOx for clinical stage III gastric cancer (OGSG1601)
2018
Adjuvant S-1+DTX therapy for Stage III gastric cancer: survival analysis of the two phase II trials (OGSG0604, OGSG1002)
測定可能病変を有していない進行再発胃癌を対象としたS-1+DTX 療法とS-1+CDDP 療法のランダム化第Ⅱ相試験(HERBIS-3 / OGSG1104)
A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (HERBIS-4B / OGSG 1106)
A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)
An Intergroup phase III trial of Ramucirumab plus Irinotecan in Third or more line Beyond Progression after Ramucirumab for advanced Gastric Cancer (RINDBeRG trial)
Randomized, Open-Label Phase II Study Comparing Capecitabine- Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial
Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202